Search Results

Intrinsic Therapeutics, Inc. announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors.

Intrinsic Therapeutics, Inc. announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device.

Intrinsic Therapeutics, Inc. today has announced the publication of results from a post-market study that the use of Barricaid in high-risk patients results in significantly fewer reherniations and reoperations when compared to patients treated with discectomy alone.

Kintara Therapeutics, Inc. today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and highly-aggressive childhood brain cancer.

FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a rare, highly aggressive and difficult to treat brain tumor found in children, has been granted Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA).

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system